Pfizer and biontech reach an agreement to supply the eu with 200 million doses of their bnt162b2 mrna-based vaccine candidate against covid-19

New york and mainz, germany, 11 november 2020 — pfizer (nyse: pfe) and biontech se (nasdaq: bntx) today announced that they have reached an agreement with the european commission to supply 200 million doses of their investigational bnt162b2 mrna-based vaccine candidate against covid-19 to european union (eu) member states, with an option for the european commission to request an additional 100 million doses. deliveries are anticipated to start by the end of 2020, subject to clinical success and regulatory authorization.
BNTX Ratings Summary
BNTX Quant Ranking